Clinical trials
2 active studies led by Epiminder America, Inc., of 2 in all
Source: ClinicalTrials.gov, Studies with Epiminder America, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public records show Epiminder America, Inc. in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Epiminder America, Inc. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
2 active studies led by Epiminder America, Inc., of 2 in all
Source: ClinicalTrials.gov, Studies with Epiminder America, Inc. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
1 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
Markets we cover where free public records show Epiminder America, Inc.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Epiminder America, Inc. is in.
Stories on the topics Epiminder America, Inc. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
Atrial fibrillation raises stroke risk about five-fold. Holter monitors, patches, implants and smartwatches…
ReadSearch all reports for Epiminder America, Inc. All companies